USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
STEMSYNERGY THERAPEUTICS, INC.
Address:
1951 NW 7th Ave
Suite 300
Miami, FL
Phone:
N/A
URL:
N/A
EIN:
120850974
DUNS:
826941754
Number of Employees:
3
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $399,451.00 2
SBIR Phase II $1,999,997.00 1

Award List:

Development of Wnt Pathway Inhibitors for Colorectal Cancer

Award Year / Program / Phase:
2010 / SBIR / Phase I
Award Amount:
$140,000.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): StemSynergy Therapeutics Inc. (SSTI) is a biopharmaceutical company focused on the discovery, development, and commercialization of drugs that target pathways fundamental to stem cells and cancer stem cells. The World H ealth Organization estimates that over 12… More

Development of Wnt Pathway Inhibitors for Colorectal Cancer

Award Year / Program / Phase:
2012 / SBIR / Phase II
Award Amount:
$1,999,997.00
Agency:
HHS
Principal Investigator:
Darren Orton – 615-973-5409
Abstract:
DESCRIPTION (provided by applicant): StemSynergy Therapeutics Inc. (SSTI) is a biopharmaceutical company focused on the discovery, development, and commercialization of drugs that target pathways fundamental to stem cells and cancer stem cells. The WorldHealth Organization estimates that over 12… More

Targeting stem cell populations in lung cancer by modulating the Wnt and p53 path

Award Year / Program / Phase:
2012 / SBIR / Phase I
Award Amount:
$259,451.00
Agency:
HHS
Principal Investigator:
Darren Orton – 615-973-5409
Abstract:
DESCRIPTION (provided by applicant): Despite significant advancements in modern medicine with regards to surgery, radiation therapy and imaging of tumors, the survival rate for patients with non-small-cell lung carcinoma (NSCLC) remain almost identical to20 years ago. Current therapies targeting the… More